PTR-1 trial protocol: primary tumor resection after afatinib induction in metastatic EGFR-mutant NSCLC

PTR-1 is an investigator-initiated, open-label, randomized phase II trial evaluating whether primary tumor resection (PTR) after disease control with afatinib improves progression-free survival (PFS) in patients with stage IV EGFR-mutant non-small-cell lung cancer. Planned enrollment is 100 participants, with an initial target of 60 randomized participants. Eligible patients are aged ≥20 years, have an EGFR exon 19 deletion or exon 21 L858R mutation, an Eastern Cooperative Oncology Group performance status of 0–1, and a technically resectable primary tumor. Participants receive 12 weeks of afatinib induction, including treatment before enrollment. Those with a partial response or stable disease who remain medically fit and surgically eligible are randomized 1:1 to PTR plus continued afatinib or afatinib alone. The primary endpoint is the 2-year PFS rate from the first afatinib dose. PFS is defined as the time from afatinib initiation to progression per RECIST version 1.1 or death from any cause. Secondary endpoints include PFS, overall survival, safety, pathological response, and resection margin status. PTR-1 evaluates whether resection of the residual primary tumor improves disease control in patients eligible for randomization after induction. Clinical trial registration www.clinicaltrials.gov identifier is NCT05215548.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-11-19
DOI
https://doi.org/10.1080/14796694.2026.2766051
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PTR-1 trial protocol: primary tumor resection after afatinib induction in metastatic EGFR-mutant NSCLC

Tzu‐Pin Lu, Pei‐Hsing Chen, Jin‐Shing Chen, Min‐Shu Hsieh et al.
Future Oncology
Lung Cancer Treatments and Mutations
article

PTR-1 trial protocol: primary tumor resection after afatinib induction in metastatic EGFR-mutant NSCLC

Tzu‐Pin Lu, Pei‐Hsing Chen, Jin‐Shing Chen, Min‐Shu Hsieh, Hsao‐Hsun Hsu, Jen Hao Chung
article en

Abstract

PTR-1 is an investigator-initiated, open-label, randomized phase II trial evaluating whether primary tumor resection (PTR) after disease control with afatinib improves progression-free survival (PFS) in patients with stage IV EGFR-mutant non-small-cell lung cancer. Planned enrollment is 100 participants, with an initial target of 60 randomized participants. Eligible patients are aged ≥20 years, have an EGFR exon 19 deletion or exon 21 L858R mutation, an Eastern Cooperative Oncology Group performance status of 0–1, and a technically resectable primary tumor. Participants receive 12 weeks of afatinib induction, including treatment before enrollment. Those with a partial response or stable disease who remain medically fit and surgically eligible are randomized 1:1 to PTR plus continued afatinib or afatinib alone. The primary endpoint is the 2-year PFS rate from the first afatinib dose. PFS is defined as the time from afatinib initiation to progression per RECIST version 1.1 or death from any cause. Secondary endpoints include PFS, overall survival, safety, pathological response, and resection margin status. PTR-1 evaluates whether resection of the residual primary tumor improves disease control in patients eligible for randomization after induction. Clinical trial registration www.clinicaltrials.gov identifier is NCT05215548.

Future Oncology
National Taiwan University (TW), National Taiwan University Hospital (TW)
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon